10/16/2026
Lilly explores ibogaine research opportunities
Pharmaceutical giant Lilly shows interest in advancing ibogaine studies.
Topic archive
ptsd
50 stories
10/9/2026
FDA seeks public input on ibogaine trials
Gabon aims to secure benefits from rising ibogaine demand
10/9/2026
Ibogaine shows promise for PTSD in veterans, Stanford study finds
A year-long study suggests ibogaine may help veterans with PTSD, but more research is needed.
9/21/2026
Presley Gerber's death highlights ibogaine treatment
Model's passing at 27 raises questions about ibogaine's role in addiction recovery.
9/17/2026
Ibogaine research advances in U.S. and Israel for PTSD
Psychedelic therapies gain momentum as potential treatments for combat-related trauma.
9/17/2026
ARPA-H ibogaine workshop emphasizes precision
ARPA-H workshop explores ibogaine's potential with a focus on precision.
9/10/2026
Rhelion Life Sciences launches ibogaine stability program
Filament Health begins stability program for IBEX011 amid rising ibogaine demand.
9/10/2026
FDA outlines new psychedelic drug framework in NEJM
The FDA highlights its evolving approach to psychedelic therapies amid a mental health crisis.
9/10/2026
Filament Health plans stability program for ibogaine drug
IBEX011 stability program aims to meet growing demand for standardized ibogaine.
9/3/2026
Veterans advocate for ibogaine access
Veterans push for ibogaine to treat PTSD and addiction.
9/1/2026
Barrow, ASU launch clinical trial for ibogaine in the US
The study aims to explore ibogaine's potential for treating PTSD and addiction.
8/26/2026
Veterans advocate for ibogaine to combat PTSD
Ibogaine shows promise for PTSD, but remains illegal in the U.S.
8/26/2026
University of Miami gifts 1994 ibogaine IND to HHS
The move promotes open science and could influence future psychedelic research.
8/21/2026
University of Miami gifts ibogaine application to Trump admin
The move could expedite psychedelic research for veteran treatment.
8/21/2026
Johnson & Johnson invests in Delix Therapeutics
Investment in neuroplastogen company highlights growing interest in non-hallucinogenic psychedelics.
8/21/2026
Ibogaine treatment footage released amid therapy push
David Dardashti shares clinical footage as psychedelic therapy gains federal interest.
8/21/2026
Ibogaine research gains momentum for PTSD treatment
Trump administration accelerates psychedelic research for veterans' mental health.
8/19/2026
Arizona study to explore ibogaine for PTSD, brain injuries
Barrow Neurological Institute to test ibogaine's safety and efficacy in a state-funded trial.
8/19/2026
Trump pushes ibogaine treatment for veterans
Trump's administration advances psychedelic therapies for PTSD and TBI in veterans.
8/19/2026
Psyence Biomedical stock rises 27% on ibogaine research
Market optimism grows as Psyence Biomedical advances ibogaine studies.
8/19/2026
Trump emphasizes ibogaine development, Psyence BioMed reacts
Former President Trump supports ibogaine research, sparking industry response.
8/19/2026
Psyence BioMed backs Trump ibogaine initiative
Company aligns with U.S. efforts to advance ibogaine research.
8/19/2026
University of Miami submits ibogaine application to federal authorities
Trump announces transfer of ibogaine investigational drug application to accelerate research.
8/19/2026
Arizona funds $5M ibogaine study for brain injuries
Barrow Neurological Institute to explore ibogaine's potential for PTSD and brain injuries.
8/16/2026
Ibogaine shows promise for treating brain disorders
Research highlights ibogaine's potential in opioid addiction and multiple sclerosis.
8/15/2026
Ibogaine offers new hope for kratom users amid bans
David Dardashti advocates ibogaine as a medical solution for kratom dependency.
8/12/2026
Ibogaine treatment: brain effects explored
NBC 7 San Diego video delves into ibogaine's impact on the brain.
8/8/2026
SAMHSA gathers experts on psychedelics
AtaiBeckley and Compass Pathways explore new opportunities.
8/7/2026
Ibogaine gains traction among conservative leaders
Rick Perry and Bryan Hubbard lead efforts to legitimize ibogaine in Texas.
8/7/2026
Ibogaine treatment explored for veterans
Ibogaine's potential in treating PTSD and opioid addiction in veterans examined.
8/6/2026
Ibogaine-related death under investigation in Cambridge
Police probe follows death linked to unauthorized ibogaine use in Canada.
8/6/2026
Barrow Institute gets $5M for ibogaine brain injury trial
The trial will explore ibogaine's potential in treating chronic TBI symptoms.
8/5/2026
Ibogaine research review highlights safety concerns
Thirty years of ibogaine studies reveal potential but highlight risks.
8/5/2026
Ibogaine death in Cambridge prompts police warning
Police charge Mississauga man after ibogaine-related death, highlighting risks.
8/5/2026
Ibogaine's impact on PTSD: A new hope for veterans
Jonathan Dickinson discusses ibogaine's potential in treating PTSD and brain injuries.
7/31/2026
Congressman Luttrell champions ibogaine for PTSD treatment
Luttrell's IBOGAINE Act aims to solidify psychedelic therapy access for veterans.
7/29/2026
Ibogaine research faces representation challenges
Psychedelic trials often exclude marginalized groups, raising questions about equity and efficacy.
7/29/2026
Scottsdale Research Institute submits IND for ibogaine
Ibogaine HCl aims to treat PTSD, TBI, and opioid use disorder.
7/29/2026
Texas initiates ibogaine research with federal support
State-led ibogaine study in Texas gains federal backing, marking a significant research development.
7/28/2026
Ibogaine inquiries on YouTube spark interest
YouTube video explores ibogaine's potential in treating disorders.
7/24/2026
Heidi Overton's role in Trump's ibogaine policy
White House adviser Heidi Overton shapes ibogaine policy amid internal disputes.
7/24/2026
Trump administration fast-tracks ibogaine research
Psychoactive drug ibogaine gains attention for addiction treatment potential.
7/24/2026
Experience Ibogaine supports 3,000 patients in recovery
The Tijuana-based center marks a milestone in ibogaine treatment for substance use disorder.
7/24/2026
Ibogaine may gain U.S. access under Trump administration
The Trump administration considers making ibogaine available for therapeutic use.
7/23/2026
McCaul supports NDAA amendment for veteran ibogaine access
The amendment aims to expand treatment options for PTSD and addiction.
7/22/2026
McCaul advocates for ibogaine access for veterans
Proposed NDAA amendment aims to expand treatment options for PTSD and TBI.
7/21/2026
Ibogaine reduces PTSD symptoms by 88% in study
Stanford Veterans Study highlights ibogaine's potential for PTSD treatment.
7/16/2026
Texas leaders advocate ibogaine research
Veterans report transformative effects from psychedelic therapy.
7/16/2026
Texas leaders advocate for ibogaine research
Veterans share recovery stories, highlighting ibogaine's potential.
7/15/2026
US backs psychedelic therapy research for veterans
Federal support for ibogaine and other psychedelics aims to aid veterans with PTSD.